2021 research period for North America is officially open
March 24, 2021
Research team is now accepting firm submissions, due June 1
US
Patent Prosecution
Patent Strategy & Management
| Patent Strategy & Management — Recommended |
|---|
| Arnold & Porter |
| Dechert |
| Fenwick & West |
| Foley & Lardner |
| Greenberg Traurig |
| Hamilton Brook Smith & Reynolds |
| Leydig Voit & Mayer |
| McDonnell Boehnen Hulbert & Berghoff |
| Morgan Lewis & Bockius |
| Venable |
| WilmerHale |
| Lawyer | Section | Practice Area | Location |
|---|---|---|---|
| Gagala, Bruce | Chicago | ||
| Hasan, Salim | Intellectual Property | Patent Strategy & Management, General Patent Litigation | Chicago |
| Kilyk, John | Intellectual Property | Patent Prosecution, Patent Strategy & Management, General Patent Litigation, Hatch-Waxman Patent Litigation | Chicago |
| Sklar, Steven | Intellectual Property | Patent Strategy & Management, Hatch-Waxman Patent Litigation | Chicago |
| , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} | , {{displayValue}} {{displayValue}} {{displayValue}} |
Intellectual Property
Leydig Voit & Mayer
Chicago-based IP firm Leydig Voit & Mayer receives national rankings for its expertise in life sciences patent prosecution and strategy. In addition to the firm's non-contentious practice, it is also notable for pharmaceutical and biotech litigation.
John Kilyk Jr is well-versed in both patent litigation and strategic counseling for clients almost exclusively in the life sciences industry. He is a previous winner of the Midwest Patent Strategy Attorney of the Year award and was shortlisted in the same category for 2020. Kilyk and a team from the firm serve as patent counsel to longstanding client National Institutes of Health in connection with its biotech and chemistry innovations.
Salim Hasan continues to advise corporations, research institutions and universities in life sciences patent matters. He brings more than 25 years of experience to his practice. Steven Sklar was recently active in multiple Hatch-Waxman disputes for clients seeking to market generic pharmaceutical products.